Lee Timothy Edward sold $32K of IVVD

Lee Timothy Edward (Chief Commercial Officer) sold 40,780 shares of Invivyd, Inc. (IVVD) at an average of $0.78 ($0.72–$0.84) across 2 trades over 2026-08-17 to 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lee Timothy Edward
Published Aug 19, 2026, 12:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 12:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IVVD
Neutral
high confidence
Mentioned
$IVVD
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IVVDNeutralLow
01

Why it matters

The disclosed fact is the sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan; the text does not include any new company fundamentals.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 designation reduces the likelihood of a fundamental repricing catalyst.

03

What to watch

The article does not state total insider holdings value, sale frequency over time, or whether other insiders sold, limiting inference from this single transaction.

Relevance 2/10Novelty 3/10Timing: Filed 2026-08-18 for sales executed 2026-08-17 to 2026-08-18.

Background

The article reports an SEC Form 4 insider transaction for Invivyd, Inc. (IVVD) by its Chief Commercial Officer.

Company-level read

Ticker impact

$IVVDNeutralHigh confidence
Context

Invivyd CCO Lee Timothy Edward sold about 40,780 shares in open-market transactions priced $0.7220 to $0.8429 per share.

Expected impact

Limited near-term impact; any reaction is likely muted unless paired with other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly pre-arranged under Rule 10b5-1, with no accompanying operational or financial disclosure in the text.

Market effects

No sector read-through is provided beyond a single-company insider sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution, which some traders may interpret as bearish.

Key entities

  • Invivyd, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Lee Timothy Edward

    Chief Commercial Officer who sold shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IVVDMed

Invivyd Posts Wider Loss In Q3 As Operating Expenses Rise

Invivyd, Inc. (IVVD) reported a wider Q3 net loss of $33.47 million, up from $10.47 million YoY, due to higher operating expenses. Revenue rose 18% to $15.45 million. The company provided updates on its pipeline, including VYD2311 for COVID-19 and VMS063 for measles, and announced leadership changes. Cash reserves totaled $126.40 million.

$IVVDHigh

Invivyd Reports Third Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights • DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communic

$IVVDMedAI 8/10

Invivyd presents preclinical data on measles antibody candidate

Invivyd (NASDAQ:IVVD) presented preclinical data for its measles antibody candidate VMS063 at IDWeek 2026, showing antiviral activity against measles virus variants. The company plans to scale up manufacturing for clinical development in 2027. There are currently no FDA-approved treatments for measles, with U.S. cases nearly double in 2026 compared to 2025, according to Invivyd.

$IVVDLow

Invivyd, Inc. (IVVD) Unveils Preclinical Data for Measles mAb VMS063

Invivyd, Inc. (IVVD) presented preclinical data for VMS063, a novel monoclonal antibody for measles, showing in vitro activity against contemporary virus variants. The company is scaling up production for clinical development in 2027. There are currently no FDA-approved treatments for measles, and the U.S. is experiencing a surge in cases.

$IVVDLowAI 8/10

More than 9 million U.S. children are estimated to lack measles protection. Lab tests found an antibody could fight measles.

Invivyd (Nasdaq: IVVD) presented preclinical data for VMS063, a monoclonal antibody candidate for measles treatment and prevention. VMS063 showed potent in vitro activity against measles virus variants. Invivyd plans to scale up production for clinical development in 2027. The U.S. is experiencing a record number of measles cases in 2026, with over 9 million children unprotected.